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Abstract
Botulinum neurotoxin serotype A (BoNTA) causes a life-threatening neuroparalytic disease known as botulism. Current
treatment for post exposure of BoNTA uses antibodies that are effective in neutralizing the extracellular toxin to prevent
further intoxication but generally cannot rescue already intoxicated neurons. Effective small-molecule inhibitors of BoNTA
endopeptidase (BoNTAe) are desirable because such inhibitors potentially can neutralize the intracellular BoNTA and offer
complementary treatment for botulism. Previously we reported a serotype-selective, small-molecule BoNTAe inhibitor with
a Ki
app value of 3.860.8 mM. This inhibitor was developed by lead identification using virtual screening followed by
computer-aided optimization of a lead with an IC50 value of 100 mM. However, it was difficult to further improve the lead
from micromolar to even high nanomolar potency due to the unusually large enzyme-substrate interface of BoNTAe. The
enzyme-substrate interface area of 4,840 A ˚2 for BoNTAe is about four times larger than the typical protein-protein interface
area of 750–1,500 A ˚2. Inhibitors must carry several functional groups to block the unusually large interface of BoNTAe, and
syntheses of such inhibitors are therefore time-consuming and expensive. Herein we report the development of a serotype-
selective, small-molecule, and competitive inhibitor of BoNTAe with a Ki value of 7606170 nM using synthesis-based
computer-aided molecular design (SBCAMD). This new approach accounts the practicality and efficiency of inhibitor
synthesis in addition to binding affinity and selectivity. We also report a three-dimensional model of BoNTAe in complex
with the new inhibitor and the dynamics of the complex predicted by multiple molecular dynamics simulations, and discuss
further structural optimization to achieve better in vivo efficacy in neutralizing BoNTA than those of our early micromolar
leads. This work provides new insight into structural modification of known small-molecule BoNTAe inhibitors. It also
demonstrates that SBCAMD is capable of improving potency of an inhibitor lead by nearly one order of magnitude, even for
BoNTAe as one of the most challenging protein targets. The results are insightful for developing effective small-molecule
inhibitors of protein targets with large active sites.
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Introduction
Botulism is a life-threatening neuroparalytic disease that occurs
in at least five forms–food-borne botulism, infant botulism, wound
botulism, adult enteric infectious botulism, and inhalation
botulism. The disease is caused by the specific action of botulinum
neurotoxins. Seven antigenically distinct botulinum neurotoxins
(serotypes A to G) are known, but primarily serotypes A, B, E, and
F have been reported to cause botulism in humans.
Botulinum neurotoxin serotype A (BoNTA) is a protein
produced by the spore-forming anaerobic bacterium, Clostridium
botulinum. The lethal doses of BoNTA for a 70-kg human are
estimated as 0.9 mg by inhalation and 70 mg by ingestion [1].
BoNTA inhibits the release of acetylcholine from presynaptic
nerve terminals at neuromuscular junctions, causing flaccid
paralysis and frequently leading to prolonged mechanical
ventilation with serious medical sequelae or death following
respiratory arrest [2]. Despite its toxicity, the purified and diluted
BoNTA has been used as medical treatment for cholinergic nerve
and muscle dysfunctions [3,4]; BoNTA (marketed as Botox) also
can temporarily reduce facial frown lines. However, overdose with
BoNTA can develop systemic botulism [5].
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7730Current post-exposure treatment of botulism relies on admin-
istration of antibodies against the toxins. The available antitoxin is
an equine product that causes allergic reactions in ,10% of
patients [6]. In late 2003, a solution of human antibodies was
licensed as ‘‘BabyBIG’’ to treat infant botulism [7], but to date
generic botulism immune globulin injections are still unavailable.
Furthermore, antibodies are effective in neutralizing the extracel-
lular toxin to prevent further intoxication but generally cannot
rescue already intoxicated neurons. There is a need to develop
complementary, post-exposure treatments such as small-molecule
antidotes that potentially can neutralize the intracellular toxin.
Structurally, BoNTA consists of a light chain (Mr ,50,000) and
a heavy chain (Mr ,100,000) that are linked by a disulfide bond.
The light-chain is a zinc endopeptidase that specifically cleaves
SNAP-25, a neuronal protein required for acetylcholine release
[8]. The BoNTA endopeptidase (BoNTAe) has been a target for
developing small-molecule inhibitors of the toxin [9–15]. Howev-
er, developing potent inhibitors is as difficult as developing small-
molecule inhibitors of protein-protein complexes. The latter has
been a known challenge for decades [16]. The difficulty arises
because, upon binding, the substrate wraps around the circum-
ference of BoNTAe constituting an unusually large substrate
enzyme interface area of 4,840 A ˚ 2 (Figure 1) [17]. This interface
requires molecules possessing several functional groups to block it.
Consequently, syntheses of such molecules are time-consuming
and costly. The extent of the challenge can be appreciated by
comparing the interface area (4,840 A ˚ 2) of BoNTAe to the typical
protein-protein interface area of 750–1500 A ˚ 2 [16]. Because of the
large-interface challenge, small-molecule BoNTAe inhibitors
reported to date typically have inhibitory potencies in the low
micromolar range (see Section 3.1). To date, the most potent
BoNTAe inhibitor has been an elegantly designed peptidic analog
that mimics GlnArgAlaThrLysMetLeu, and this heptapeptidic
mimetic (HPM) has a Ki value of 41 nM [18]. Nevertheless, some
of the reported micromolar small-molecule inhibitors already
demonstrate ex vivo efficacy in protecting cells against BoNTA
[9,11]. Our micromolar small-molecule BoNTAe inhibitor leads
also demonstrate in vivo efficacy at a concentration of 2 mg/kg in
protecting mice against 5 LD50 challenge of BoNTA (manuscript
in preparation). These results suggest that BoNTAe is a viable
target for developing small-molecule antidotes to BoNTA.
Previously we reported a serotype-selective, small-molecule
BoNTAe inhibitor with a Ki
app value of 3.860.8 mM [10]. This
inhibitor was developed by lead identification using virtual
screening followed by optimization of a lead with an IC50 value
of 100 mM [19]. However, we were unable to further improve the
lead from micromolar to even high-nanomolar potency using
conventional computer-aided molecular design (CAMD), despite
the use of a high-resolution BoNTAe crystal structure (free and in
complex with a peptidic substrate analog) [20] and advanced
terascale computer simulation techniques [10].
In this article, we report the development of a serotype-selective,
small-molecule, and competitive inhibitor of BoNTAe with a Ki
value of 7606170 nM by using a new approach, termed synthesis-
based computer-aided molecular design (SBCAMD), to address
the challenge in synthesis. We also report a three-dimensional (3D)
model of the high-nanomolar inhibitor in complex with BoNTAe
and the dynamics of the complex predicted by multiple molecular
dynamics simulations (MMDSs). On the basis of the 3D model, we
discuss insights into further structural optimization to achieve Ki
values comparable to that of HPM and the prospect of small-
molecule BoNTAe inhibitors as effective antidotes to neutralize
the intracellular BoNTA. We also discuss the advantages of both
SBCAMD and CAMD in drug discovery.
Results
Inhibitor Design
MMDSs on our early lead 1 (Figure 2) [10] suggested that
structures like analog 2 (Figure 2) have higher affinities for
BoNTAe than 1. This is because (1) one diphenylmethanol group
of 2 can adopt the Venus-flytrap-like conformation to grasp
Arg363 of BoNTAe more tightly via cation-pi interactions than
the phenyl group of 1; (2) the other diphenylmethanol group can
fill the large void of the BoNTAe active site and interact with
Arg231 via cation-pi interactions, whereas 1 cannot reach Arg231;
(3) two ammonium groups of 2 rather than only one ammonium
group of 1 can interact with four carboxylates (Glu55, Glu64,
Glu164, and Glu257) at the active site.
However, we could not make 2 using the scheme shown in
Figure S1 in a short period, nor could we make analog 6 (Figures 2
and S2), a thiophene analog of 2, given the same time constraint.
We subsequently replaced the pyrrole ring of 2 with a benzene
ring to avoid the problem of making 2. This transformation
resulted in analogs 3–5 (Figure 2) that can be made with facile
syntheses described in the schemes shown in Figure S3, Figure S4,
and Figure S5, although these molecules are more bulky than 2
and carry an aromatic hydroxamate that has a relatively low
affinity for zinc due to pi-electron delocalization. We initially
hoped that the bulkiness problem could be remedied by the
flexibility of the BoNTAe active site and therefore made 3–5 with
ease. However, biological evaluation showed that none of these
analogs was active in inhibiting BoNTAe at an inhibitor
concentration of 10 mM (Table 1). Although change of an
aromatic hydroxamate to an aliphatic hydroxamate does not
require too much synthetic effort, we did not pursue this
modification, as it would make these molecules even more bulky.
Alternatively, we made analog 7 (Figure 2) as a truncated analog
of 6 according to the scheme shown in Figure S6. Unexpectedly, 7
precipitated in the inhibition assay buffer even though dimethyl
sulfoxide was used to dissolve 7. Gratifyingly, a different
truncation of 6 led to the syntheses of analogs 8 and 9 (Figure 2)
according to Schemes I–III of Figure 3. Encouragingly, both 8 and
9 showed 35% inhibition of BoNTAe at an inhibitor concentra-
tion of 10 mM (Table 1). These results inspired the design of
analog 10a (Figure 2). The replacement of the thiophene ring of 8
by a pyrrole ring in 10a was due to our synthetic experience and
available intermediates of the unsuccessful synthesis of 2.I n
making 10a according to Schemes I and IV of Figure 3, we had to
protect the pyrrole nitrogen atom in order to improve the yield of
the Sonagashira coupling [21]. However, we could not cleave the
p-methoxybenzyl or benzyl group from the pyrrole nitrogen atom,
nor could we protect the nitrogen atom using tosyl chloride.
Nonetheless, according to the inhibitor-bound BoNTAe complex-
es generated by MMDSs, we conjectured that the benzyl group of
10b could interact favorably with the serotype-specific Phe194 via
the pi-pi interaction. We therefore completed the synthesis of 10a
without cleaving the benzyl group to give 10b. More encourag-
ingly, 10b at 10 mM showed 64% inhibition of BoNTAe (Table 1).
A structure-activity relationship study on a series of homologues of
10b with two identical alkylamino chain lengths varying from 6 to
10 methylene groups identified N,N-bis(7-aminoheptyl)-1-benzyl-
5-(3-(hydroxy-3,3-diphenylpropyl)-4-(3-hydroxyamino)-3-oxopro-
pyl))-1H-pyrrole-2-carboxamide (AHP, see Figure 2) as the most
potent of the series (see Section 2.4 for characterization of AHP).
To confirm the conjecture about the interaction of the benzyl
group with Phe194, we also made analog 11 with a methyl group
attached to the pyrrole nitrogen atom of 11 (Figures 2 and 3).
Indeed, 11 at 1 mM showed only 8% inhibition of BoNTAe,
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PLoS ONE | www.plosone.org 2 November 2009 | Volume 4 | Issue 11 | e7730Figure 1. Large enzyme-substrate interface of BoNTAe. A: top view of the active site showing the substrate binding at the large pocket. B: side
view of the active site showing the substrate wrapping around the circumference of BoNTAe. Active-site residues of BoNTAe (Zn
+2, H223, H227, E262,
F163, F194, R363, and D370) are shown in light blue sphere or light blue stick model. The SNAP-25 substrate (146–204) is shown in red stick model.
BoNTAe is shown in grey surface model with 15% transparency.
doi:10.1371/journal.pone.0007730.g001
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PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7730Figure 2. Chemical structures of BoNTAe inhibitors and their analogs resulted from SBCAMD.
doi:10.1371/journal.pone.0007730.g002
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(Table 1).
Computer Simulation
Twenty different molecular dynamics simulations (each lasted
10 ns) were carried out for the AHPNBoNTAe complex to probe
the intermolecular interactions of the design inhibitor using the
PMEMD module of the AMBER 8 program [22] (see Section 4.4).
The initial complex structure was generated by manually docking
AHP into the BoNTAe active site with (1) the hydroxamate group
near the active-site zinc ion, (2) the diphenylmethanol group near
Arg363, (3) the benzyl group near Phe194, (4) one ammonium
group near Glu55 and Glu164, and (5) the other ammonium
group near Glu257. The BoNTAe structure used for the docking
was taken from the crystal structure of an inhibitor-bound
BoNTAe (Protein Data Bank Code: 3BOO [20]) in which
conformations of missing residues 62–67 were taken from the
crystal structure of a BoNTAe mutant in complex with SNAP-25
(Protein Data Bank Code: 1XTG [17]).
For each of the 20 simulations, 200 instantaneous conforma-
tions were saved at 5-ps intervals during the last 1-ns period. A
total of 4,000 instantaneous conformations of AHPNBoNTAe from
the 20 simulations were subjected to a cluster analysis using the
averagelinkage algorithm (epsilon=2.0 A ˚ and RMS on alpha-
carbon atoms) [23] implemented in the PTRAJ module of the
AMBER 10 program [22]. Only one cluster of the BoNTAe
conformations was identified.
All 4,000 instantaneous conformations of AHPNBoNTAe were
subjected to a second-round cluster analysis using the averagelink-
age algorithm (epsilon=2.0 A ˚ and RMS on all atoms of AHP).
This analysis identified five clusters of the AHP conformations.
The numbers of the AHP conformations in Clusters 1–5 are 2400,
600, 721, 200, and 79, respectively. Of the three most populated
clusters (Figure 4), the AHP conformations in Clusters 1 and 3 are
similar, and the one in Cluster 2 is unique. All inhibitor
conformations in Clusters 1–3 have one ammonium group
forming a salt bridge to Asp370, although this group was placed
away from Asp370 but close to Glu257 in the initial conformation
used in the MMDSs. For the inhibitor conformations in Cluster 2,
the other ammonium group moved away from Glu56 and Glu164,
and the ammonium group of Lys66 moved close to the two
carboxylates to form salt bridges, although the ammonium groups
of AHP and Lys66 were placed close to and away from
the carboxylates in the initial conformation, respectively. For
the inhibitor conformations in Clusters 1 and 3, the Glu56-
interacting ammonium group of AHP and the Lys66 ammonium
group remained in the same locations as those in the initial
conformation.
To investigate whether AHP adopts two different conforma-
tions found in Clusters 1 and 2 or one of the two, a second round
of 20 10-ns-long simulations on AHPNBoNTAe were carried out
using the representative conformation of AHPNBoNTAe in Cluster
2 as an initial conformation. The same cluster analyses of the
second-round simulations identified again one cluster of the
BoNTAe conformations and five clusters of the AHP conforma-
tions. The numbers of the inhibitor conformations in Clusters 1–5
of the second-round simulations are 459, 201, 2762, 178, and 400,
respectively. Interestingly, the most populated inhibitor confor-
mation (Cluster 3) of the second-round simulations is nearly
identical to the third most popular inhibitor conformation (Cluster
2) of the first-round. However, the most popular inhibitor
conformation (Cluster 1) of the first-round simulations disappeared
in the second-round, suggesting that AHP adopts only one
conformation in the BoNTAe active site.
Deviations for all alpha-carbon atoms between the representa-
tive conformation of Cluster 3 of the second-round simulations
and the free BoNTAe crystal structure (Protein Data Bank Code:
3BON [20]) that was aligned over the representative conformation
were computed and plotted against temperature factors of the
corresponding alpha-carbon atoms (Figure 5). A similar plot was
also obtained from the average conformation of Cluster 3 of the
second-round simulations (Figure 5). It is worth noting that only
alpha-carbon atoms were used for the alignment and that no
energy minimization was performed on the representative or
average conformation. As apparent from these correlation plots,
the alpha-carbon deviations of the representative and average
conformations are consistent with temperature factors for all
residues except for terminal residues or residues that are involved
in crystal contact such as residues 197–213, 244–257, 283–295,
and 375–387. The representative conformation of AHPNBoNTAe
in Cluster 3 of the second-round simulations has a free-and-cool
root mean square deviation (C&F RMSD) of 1.06 A ˚ for all alpha-
carbon atoms of the protein relative to those of the crystal
structure. The C&F RMSD [24] is the RMSD of residues that are
not involved in crystal contact and have temperature factors lower
than the average temperature factors, and it is used to minimize
the structural difference caused by crystal packing [25–27] and
high temperature factors. Consistently, the average conformation
of AHPNBoNTAe in Cluster 3 of the second-round simulations has
a C&F RMSD of 0.85 A ˚. These results suggest that the average or
representative conformation in Cluster 3 of the second-round
simulations best represents the AHPNBoNTAe complex structure
in water. The coordinates of the average and representative
conformations are available from Datasets S1 and S2 of
Supporting Information.
In the representative conformation of AHPNBoNTAe (Figures 6A
and6B),the hydroxamategroupcoordinatesthezincionand has(1)
a hydrogen bond to Glu224, (2) a one-water-mediated hydrogen-
bond network to Tyr366, and (3) a one-water-mediated hydrogen-
bond network to Arg363; the two hydroxamate-linking methylene
groups have van der Waals interactions with the methyl and
methylene groups of Thr220 and Glu224, respectively; the
diphenylmethanol group has (1) cation-pi interactions with
Arg363, (2) pi-pi interactions with Tyr366, Phe194, and Phe196,
Table 1. Relative BoNTAe inhibition activities of AHP and its
analogs.
Inhibitor % Inhibition of BoNTAe
1 46% at 10 mM
2 Not made
3 0% at 10 mM
4 3% at 10 mM
5 1% at 10 mM
6 Not made
7 Precipitated in assay buffer
8 35% at 10 mM
9 35% at 10 mM
10a Not made
10b 64% at 10 mM
11 8% at 1 mM
AHP 54% at 1 mM
doi:10.1371/journal.pone.0007730.t001
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hydrogen-bond network to Asp203; the benzyl group has pi-pi
interactions with Phe194 and Phe419; the pyrrole-substituted
carbonyl oxygen atom has a one-water-mediated hydrogen-bond
network to Gln162; one ammonium group has a salt bridge with
Asp370 and an intramolecular cation-pi interaction with the
diphenylmethanol group; the other ammonium group is placed at
the mid point to the carboxylates of Glu55, Glu64, and Glu164 and
has ionic interactions with these carboxylates; the alkyl chain of the
Glu55-interacting ammonium group hasvander Waals interactions
with the methylene groups of Glu164, Lys66, and Gln162.
In the average conformation of AHPNBoNTAe (Figure 6C),
there is significant contraction for the benzyl group and the
alkyl ammonium group that interacts with Glu55, Glu64, and
Glu164. The contraction of the benzyl group indicates that it
spins in a hydrophobic pocket constituted by Val70, Ile161,
Phe194, Val373, and Phe419. It also indicates that the alkyl
ammonium group is highly mobile in interacting with Glu55,
Glu64, and Glu164. The inhibitor dynamics revealed by the
MMDSs suggests that the binding of AHP to BoNTAe is partly
entropy-driven. It also suggests that the electron density for the
benzyl group will be slightly disordered and that the electron
Figure 3. Syntheses of BoNTAe inhibitors 8, 9, 10b, 11, and AHP. Scheme I: synthesis of intermediate 14; Scheme II: synthesis of 8; Scheme III:
synthesis of 9; Scheme IV: syntheses of 10b, 11, and AHP.
doi:10.1371/journal.pone.0007730.g003
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disordered in the crystal structure of AHPNBoNTAe to be
determined.
Chemical Synthesis
AHP,a nachiral molecule possessing five functional groups
(hydroxamate, diphenylmethanol, benzyl, and two ammonium
groups) designed to interact with the active-site residues of
BoNTAe, was made readily with a 10-step synthesis outlined in
Schemes I and IV of Figure 3. This synthesis began with methyl 4-
formyl-1H-pyrrole-2-carboxylate (33) that has a pyrrole ring as a
frame to support the five functional groups in different
orientations. This expensive commercially available starting
material was, however, made in-house from 2-(trichloroacetyl)-
pyrrole using a two-step synthesis according to published protocols
[28,29]. To introduce the diphenylmethanol group to the pyrrole
ring via the Sonagashira coupling [21], I2 and CF3CO2Ag in
CHCl3 [29] were used to iodinate intermediate 33 to give the
desired intermediate 34, which was separable from methyl 4-
formyl-3,5-diiodo-1H-pyrrole-2-carboxylate and methyl 4-formyl-
3-iodo-1H-pyrrole-2-carboxylate through column chromatogra-
phy. Another reported procedure [30] was also effective in
converting 33 to 34 in a similar yield. N-Benzylation of 34
followed by the Sonagashira coupling [21] with 1,1-diphenylprop-
2-yn-1-ol gave intermediate 36x with both diphenylmethanol and
benzyl groups linked to the pyrrole ring, which was confirmed by
the heteronuclear multiple bond coherence (HMBC) spectroscopy.
Saponification of 36x followed by amidation using intermediate
14y gave intermediate 38z with two protected alkylamino groups
linked to the pyrrole ring, wherein 14y was obtained from N-(7-
bromoheptyl)-phthalimide in a high yield via a two-step synthesis
outlined in Scheme I of Figure 3. Wittig olefination of 38z gave
intermediate 39z with an ethyl ester as a precursor of the desired
hydroxamate group. The two unsaturated bonds of 39z were
reduced by dry 10% Pd-C in ethyl acetate to give intermediate
40z. The hydrogenation reaction was very sensitive to moisture;
wet Pd-C or Raney nickel resulted in unidentified products. The
final product (AHP) was obtained by treating 40z with excess of
50% aqueous hydroxylamine for 24 hours [31]. This treatment
converted the ethyl ester and N-phthalimides to hydroxamic acid
and amines, respectively [32,33]. High performance liquid
chromatography (HPLC) purification using TFA-containing
solvent yielded pure AHP in its TFA salt form. Caution should
be taken in removing TFA-containing eluent after HPLC, as the
diphenylmethyl hydroxy group of AHP is prone to elimination
under acidic conditions (see Section 4.2.7).
Biological Testing
According to HPLC-based kinetics assays described in Section
4.3 [34], AHP has a Ki value of 7606170 nM, which was
calculated from slopes of Dixon plots (Figure 7) with Ki=KM/
[(slope)(VMAX)(S)], where (S) is the substrate concentration [35]
and kinetic constants for the substrate were taken from reference
[36]. Unlike inhibitor 1 as we reported previously [10], AHP has
linear Dixon plots (Figure 7) indicating that AHP is a competitive
inhibitor of BoNTAe and its Ki value can thus be obtained from
the fractional inhibition method or the Cheng and Prusoff method
[35,37]. Indeed, both methods yielded a Ki value of 7606170 nM,
consistent with the value from the Dixon plots. AHP did not
inhibit botulinum neurotoxin serotype B endopeptidase (BoNTBe)
at concentrations up to 5 mM at which AHP showed .80%
inhibition of BoNTAe. As described in Section 4.3, the BoNTAe
inhibition assay buffer was supplemented by 25 mM ZnCl2,
whereas the BoNTBe inhibition assay buffer contained no
exogenous zinc ion. AHP at 5 mM showed .80% inhibition of
BoNTAe in the presence of 5-molar excess of exogenous zinc, but
it did not show any BoNTBe inhibition in the absence of
exogenous zinc. These results preclude the possibility that AHP
nonspecifically inhibited BoNTAe through depleting the active-site
zinc divalent cation via zinc chelation. Clearly, AHP is a serotype-
selective, small-molecule, and competitive inhibitor of BoNTAe
with a Ki value of 7606170 nM.
Figure 4. Overlays of AHP conformations of the three most
populated clusters from the MMDSs. A (row 1): Clusters 1 (green),
2 (magenta), and 3 (yellow) from the first-round; B (row 2): Clusters 1
(yellow), 3 (green), and 5 (magenta) from the second-round; C (row 3):
Cluster 2 (magenta) of the first-round and Cluster 3 (green) of the
second-round; D (row 4): Cluster 1 (green) of the first-round and Cluster
5 (magenta) of the second-round.
doi:10.1371/journal.pone.0007730.g004
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Relative Potencies of BoNTAe Inhibitors
A mixture of two regioisomeric small molecules has been
reported to have a Ki value of 6006100 nM in inhibiting BoNTAe
[38]; however, there has been no report for the separation of the
mixture. To our knowledge, the most potent BoNTAe inhibitor
has been HPM,apeptidic inhibitor with a Ki value of 41 nM [18].
A small-molecule BoNTAe inhibitor, 2,4-dichlorocinnamic hydro-
xamate (DCCH), was reported to have initially a Ki value of
300612 nM [39] and most recently an IC50 value of 59 or 81 mM
depending on assay conditions [40]. Using the assay conditions
described in Section 4.3 that are different from those reported in
[39,40], we found that the IC50 values of AHP and DCCH are
,1 mM and 34 mM, respectively, and that AHP is .34-fold more
potent in inhibiting BoNTAe than DCCH [39] and one order of
magnitude less potent than HPM [18]. Given this rank order of
potency, below we discuss new insights into BoNTAe inhibitor
design and new approaches that facilitate such design.
Insights into BoNTAe Inhibitor Design
While crystal structures of HPMNBoNTAe and DCCHNBoN-
TAe have been reported [18,41], the determination of the crystal
structure of AHPNBoNTAe is currently underway. The results
described in Section 2.2 suggest that the computer model of
AHPNBoNTAe is suitable for qualitative comparison of the
binding of AHP at the BoNTAe active site with those of HPM
and DCCH.
As apparent from the cross-section view of the inhibitor-bound
BoNTAe active site (Figure 8), DCCH occupies a small portion of
the active-site region where the Arg198-containing hydrolysis
product binds [17]; AHP occupies the bottom half of that region;
HPM occupies nearly the entire region. The rank order of
occupancy in the active site for the three inhibitors agrees well with
the rank order of the inhibitory potency described in Section 3.1.
From structural point of view, this agreement suggests that
effective BoNTAe inhibitors have volumes that are comparable to
or more than that of AHP. The ‘‘bulkiness’’ requirement observed
is consistent with the reported nanomolar inhibitors of BoNTBe
[42]. Therefore, we anticipate that optimization of known small-
molecule BoNTAe inhibitors by small structural perturbations
alone is unlikely to lead to effective BoNTAe inhibitors.
To obtain more potent nanomolar small-molecule BoNTAe
inhibitors, we think that new functional groups have to be
introduced to AHP to occupy the upper portion of the active-site
region. However, the more functional groups are introduced, the
more challenging the inhibitor synthesis will become. In addition,
adding more functional groups can hamper cell permeability. For
these reasons, sophisticated computer simulations such as MMDSs
employing the cationic dummy atom approach to simulating zinc
proteins [19,43–45] are needed to identify new functional groups.
These groups must have high affinities for the BoNTAe active site
and low molecular weights to maintain cell permeability. In our
view, for a realistic prospect of obtaining nanomolar BoNTAe
inhibitors able to antagonize the intracellular BoNTA, the design
and optimization of current BoNTAe inhibitor leads may need
new approaches such as the nonbonded bivalence approach [46]
that dimerizes composite inhibitors by intermolecular interactions
(self-assembly) rather than covalent bonds in order to improve
both affinity and permeability.
Synthesis-Based Computer-Aided Molecular Design
Despite the use of high-performance computing to predict
inhibitor affinity and serotype selectivity in developing our small-
molecule BoNTAe inhibitors, we recognized that the development
process is still a brute force process for at least two reasons. First,
exquisitely designed inhibitors such as inhibitor 2 may not be
synthetically accessible within a reasonable amount of time.
Second, like analog 7, newly made inhibitors may not dissolve in
an assay buffer under a high ionic strength condition. Identifica-
tion of these problems a priori is beyond the scope of current
computer simulations. The best way to circumvent these problems
is to make and test more inhibitors with good affinities predicted
by computer simulations. This requires facile synthesis of more of
such inhibitors, which is, however, different from high-throughput
screen of any available chemicals. Therefore, the ability to obtain
nanomolar BoNTAe inhibitors relies more on expeditious
syntheses of inhibitor analogs with good affinities than on exquisite
design of high-affinity inhibitor analogs using free energy
perturbation calculations that can compute the absolute binding
free energy [10].
With these considerations, we pursued synthesis-based comput-
er-aided molecular design (SBCAMD) that accounts the practi-
cality and efficiency of inhibitor synthesis in addition to binding
affinity and selectivity. The general form of our proposed
approach comprises (1) identification of an inhibitor lead with
the aid of computer simulations (e.g., identifying 2 by MMDSs); (2)
transformation of the lead to molecules that can be made in a
Figure 5. Deviations for alpha carbons between the BoNTAe crystal structure and the aligned MMDS-generated AHPNBoNTAe and B
factors for the corresponding alpha carbons of the crystal structure. The crystal structure was taken from Protein Data Bank (Code: 3BON
[20]). The representative (rep) and average (avg) conformations of AHPNBoNTAe were obtained from the second-round MMDSs. Horizontal axis:
residue ID; vertical axis: alpha-carbon deviation in A ˚ and B factors scaled by 10% in A ˚2.
doi:10.1371/journal.pone.0007730.g005
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PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7730Figure 6. Close-up view of the intermolecular interactions of AHP with the active-site residues of BoNTAe. A (top): representative
conformation generated by the second-round MMDSs; B (middle): diagram of the intermolecular interactions between AHP and BoNTAe; C (bottom):
average conformation generated by the second-round MMDSs.
doi:10.1371/journal.pone.0007730.g006
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(3) re-evaluation of the synthetically accessible molecules with
computer simulations (e.g., confirming the intermolecular interac-
tions of AHP through MMDSs), this step may not be necessary if
inhibitor synthesis takes less time than computer simulations; (4)
synthesis and evaluation of the molecules from Step 2 or 3 (e.g.,
synthesizing and testing AHP).
From synthetic chemistry point of view, SBCAMD uses a facile
synthetic scheme to transform commercially available or known
chemicals into a molecule that fits or likely fits the binding site of a
drug target. In this case, the target molecule is determined with
consideration of its synthetic effort. In contrast, CAMD uses
retrosynthetic analysis [47] to repeatedly transform a target
molecule as a potential inhibitor of a drug target into simpler
precursors until commercially available or known molecules are
reached. In this case, like a natural product, the target molecule is
pre-determined regardless of its synthetic effort.
SBCAMD is proposed to work with large-binding-pocket
targets, while CAMD works best with small-binding-pocket
targets. There are knowingly a number of factors (such as
solubility in an assay buffer) that are beyond the scope of current
computer simulations, but govern the potency of an inhibitor.
Therefore, the more inhibitors are tested, the more likely a better
inhibitor can be identified. The CAMD approach works well with
small-binding-pocket targets, even though it does not address
practicality and efficiency of chemical synthesis for each
‘‘computer-identified’’ inhibitor to be tested. This is because
inhibitors for this kind of targets are structurally simple and often
commercially available or can be made without too much
synthetic effort. When bulky inhibitors are needed to bind a large
protein pocket, such inhibitors are structurally complex and
generally commercially unavailable. Therefore, inhibitor syntheses
inevitably become the rate determine step of the development
process, and hence SBCAMD comes into play.
More case studies are certainly needed, however, in our view,
SBCAMD holds promise in developing small-molecule BoNTAe
inhibitors or other small-molecules inhibitors that bind at large
interfaces, because it aims to reduce the number of chemicals to be
tested relative to the number of chemicals used in the high
throughput screen and the time and cost to make each chemical to
be tested.
Conclusion
We developed a serotype-selective, small-molecule, and
competitive inhibitor of BoNTAe with a Ki of 7606170 nM.
We also developed a 3D model of BoNTAe in complex with the
inhibitor, which supports the concept underlying the design of
t h ei n h i b i t o r .T h e s ed e v e l o p m e n t sw e r em a d ep o s s i b l eb yt h eu s e
of a new approach (SBCAMD) that aims to reduce the number of
Figure 7. Dixon plots for competitive inhibition of BoNTAe by
AHP.
doi:10.1371/journal.pone.0007730.g007
Figure 8. Cross-Section Views of HPM, AHP, and DCCH bound in the BoNTAe active site. Left: HPM with carbon in yellow obtained from
the crystal structure of 3DS9 [18]; middle: AHP with carbon in green obtained from the MMDS-generated model; right: DCCH with carbon in blue
obtained from the crystal structure of 2IMA [41]. Oxygen, nitrogen, and zinc are shown in red, blue, and light blue, respectively. BoNTAe is shown in
white surface model with 15% transparency.
doi:10.1371/journal.pone.0007730.g008
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chemical to be tested. The results provide insights into
developing effective small molecules that can neutralize the
intracellular BoNTA to provide a therapy complimentary to
current antibody therapy for treating botulinum. This work offers
an example of the use of SBCAMD to improve expeditiously the
potency of an inhibitor lead by nearly one order of magnitude for
BoNTAe that is arguably one of the most challenging protein
targets.
Materials and Methods
Reagents
Hexanes (Hex), ethyl acetate (EtOAc), and TFA were purchased
from Fisher Scientific (Pittsburgh, PA) and used without
purification. CF3CO2Ag and 1,1-diphenylprop-2-yn-1-ol were
purchased from Aldrich Chemical Co Inc (Milwaukee, WI). Dry
Pd-C catalyst was purchased from Strem Chemicals Inc (New-
buryport, MA). All other commercially available reagents were
used as received. Recombinant BoNTAe was provided by Dr.
Leonard Smith of the United States Army Medical Research
Institute of Infectious Diseases, Fort Detrick, MD. BSA, HEPES
buffer, and zinc chloride were purchased from Sigma-Aldrich (St.
Louis, MO). Dithiothreitol was obtained from BioRad (Hercules,
CA).
Chemical Synthesis
General description. The
1H (400 MHz) and
13C NMR
(100 MHz) spectra were recorded on a Mercury 400 spectrometer
from Varian (Palo Alto, CA). Chemical shifts are reported in
ppm using either tetramethylsilane or the solvent peak as an
internal standard. Data are reported as follows: chemical shift,
multiplicity (s=singlet, brs=broad singlet, d=doublet, t=triplet,
brt=broad triplet, q=quartet, m=multiplet), coupling constant,
and integration. High-resolution mass spectra were obtained
on a Bruker BioTOF II ESI. IR spectra were obtained on a
Nicolet Continumm Infrared Microscope FT-IR using KBr pellet.
Medium pressure liquid chromatography (MPLC) was performed
with Biotage SP-1 (Charlottesville, VA) using silica gel (EM
Science, 230–400 mesh). HPLC was carried out on a
5-mm C18 column (analytical: 4.606250 mm, HyperClone;
semi-preparative: 21.26250 mm, Gemini) from Phenomenex
(Torrance, CA) eluting with linear gradient of 80% of solution A
(1000 mL of H2O and 1 mL of TFA) to 100% of solution B
(100 mL of H2O, 900 mL of MeCN and 1 mL of TFA) over 20
minutes at a flow rate of 1.0 mL/min (analytical) or over a
specified amount of time at a flow rate of 10 mL/min (semi-
preparative) with UV detection at 254 nm on a Beckman Coulter
System Gold HPLC system (166P detector and 125P solvent
module) from Beckman Coulter (Brea, CA). Benzotriazol-1-
yloxytris(dimethylamino)phosphonium hexafluorophosphate, 1-
hydroxy benzotriazole, para-toluene sulfonic acid hydrate, and
N-methyl morpholine are abbreviated as BOP, HOBt, p-TSA
hydrate, and NMM, respectively. KCN is highly toxic and must be
handled with extreme care by trained personnel.
Synthesis of intermediate 14. 2,29-(6,69-(Benzylazanediyl)
bis(hexane-6,1-diyl))diisoindoline-1,3-dione (13x). To a stirred
solution of 12x (10.73 g, 30.8 mmol) in MeCN (250 mL) was
added K2CO3 (7.74 g, 56.0 mmol) and benzylamine (1.50 g,
14.0 mmol). The resulting solution was refluxed for 36 hours. The
reaction mixture was cooled to room temperature, filtered and the
filtrate was concentrated in vacuo. MPLC purification of the residue
(Hex:EtOAc/70:30) gave 13x as a yellow viscous oil (6.7 g, 85%).
1H NMR (CDCl3) d 7.83–7.77 (m, 4H), 7.71–7.65 (m, 4H),
7.29–7.23 (m, 4H), 7.20–7.14 (m, 1H), 3.63 (t, J=7.2 Hz, 4H),
3.48 (s, 2H), 2.34 (t, J=7.2 Hz, 4H), 1.68–1.58 (m, 4H), 1.48–1.36
(m, 4H), and 1.33–1.24 (m, 8H);
13C NMR (CDCl3) d 168.65,
140.32, 134.04, 132.37, 129.04, 128.27, 126.83, 123.35, 58.74,
53.77, 38.24, 28.86, 27.21, and 27.01.
2,29-(6,69-Azanediylbis(hexane-6,1-diyl))diisooindoline-1,3-dione
(14x). To a stirred solution of 13x (1.00 g, 1.8 mmol) in
MeOH:EtOAc (1:1, 20 mL each) was added 10% Pd-C (0.35 g).
The resulting mixture was stirred at room temperature for 24 hours
under a balloon of hydrogen. The reaction mixture was filtered
through Celite and the filtrate was concentrated in vacuo. MPLC
purification of the residue (Hex:EtOAc/70:30) gave 14x as an
amorphous white solid (0.82 g, 98%).
1H NMR (CD3OD) d
7.84–7.78(m, 8H),3.67(t, J=7.2 Hz, 4H), 2.97 (t, J=7.6 Hz, 4H),
1.74–1.62 (m, 8H), and 1.50–1.34 (m, 8H);
13C NMR (DMSO-d6) d
168.65, 135.08, 132.25, 123.68, 47.27, 37.95, 28.47, 26.49, 26.28,
and 26.20.
2,29-(7,79-(Benzylazanediyl)bis(heptane-7,1-diyl))diisoindoline-1,
3-dione (13y). Intermediate 13y was obtained as a yellow oil
(6.29 g, 81%) from 12y (9.40 g, 29.0 mmol), K2CO3 (7.60 g,
55.0 mmol) and benzylamine (1.48 g, 13.8 mmol) following the
procedure described for the synthesis of 13x.
1H NMR (CDCl3) d
7.86–7.80 (m, 4H), 7.72–7.66 (m, 4H), 7.30–7.24 (m, 4H),
7.24–7.16 (m, 1H), 3.65 (t, J=7.2 Hz, 4H), 3.50 (s, 2H), 2.35 (t,
J=7.2 Hz, 4H), 1.70–1.62 (m, 4H), 1.48–1.38 (m, 4H), and
1.38–1.18 (m, 12H);
13C NMR (CDCl3) d 168.61, 140.42, 134.04,
132.37, 129.03, 128.24, 126.79, 123.33, 58.80, 53.91, 38.24,
29.33, 28.80, 27.48, 27.13, and 27.07.
2,29-(7,79-Azanediylbis(heptane-7,1-diyl))diisidioindoline-1,3-
dione (14y). Intermediate 14y w a so b t a i n e da sa na sa n
amorphous white solid (1.05 g, 82%) from 13y (1.50 g,
2.5 mmol) following the procedure described for the synthesis
of 14x.
1HN M R( C D 3OD) d 7.85–7.81 (m, 4H), 7.81–7.76 (m,
4H), 3.65 (t, J=7 . 2H z ,4 H ) ,2 . 5 6( t ,J=7.6 Hz, 4H), 1.70–1.60
(m, 4H), 1.55–1.45 (m, 4H), and 1.45–1.30 (m, 12H);
13C NMR
(DMSO-d6) d 168.59, 135.03, 132.24, 123.65, 49.96, 38.03,
29.99, 29.21, 28.55, 27.37, and 26.93.
2,29-(10,109-(Benzylazanediyl)bis(decane-10,1-diyl))diisoindo-
line-1,3-dione (13z). Intermediate 13z w a so b t a i n e da say e l l o w
viscous oil (5.67 g, 86%) from 12z (7.5 g, 20.5 mmol), K2CO3
(5.36 g, 38.8 mmol) and benzylamine (1.04 g, 9.7 mmol) fol-
lowing the procedure described for the synthesis of 13x.
1H
NMR (CDCl3) d 7.86–7.80 (m, 4H), 7.72–7.69 (m, 4H),
7.32–7.19 (m, 5H), 3.67 (t, J=7.2 Hz, 4H), 3.52 (s, 2H), 2.36
(t, J=7.2 Hz, 4H), 1.70–1.60 (m, 4H), 1.47–1.38 (m, 4H), and
1.38–1.18 (m, 24H).
13CN M R( C D C l 3) d 168.62, 140.06
134.03, 132.36, 129.10, 128.27, 126.86, 123.33, 58.69, 53.89,
38.25, 29.76, 29.72, 29.66, 29.55, 29.39, 28.81, 27.61, 27.07,
and 27.02.
2,29-(10,109-Azanediylbis(decane-10,1-diyl))diisoindoline-1,3-
dione (14z). Intermediate 14z w a so b t a i n e da sa na sa n
amorphous white solid (602 mg, 55%) from 13z (1.27 g,
1.87 mmol) following the procedure described for the synthesis
of 14x.
1HN M R( C D 3OD) d 7.86–7.81 (m, 4H), 7.81–7.76 (m,
4H), 3.65 (t, J=7.2Hz,4H),2.96(t,J=7.6 Hz, 4H), 1.72–1.60
(m, 8H), and 1.44–1.28 (m, 24H). 13C NMR (DMSO-d6) d
168.61, 135.06, 132.23, 123.66, 47.28, 38.03, 29.44, 29.18,
28.54, 26.91, 26.66, and 26.04.
Synthesis of analog 8. tert-Butyl 5-bromo-4-methylthiophene-
2-carboxylate (16). 4-Methylthiophene-2-carboxylic acid [48]
(1.42 g, 10.00 mmol) was dissolved in MeCN (30 mL), followed
by NBS (1.78 g, 10.00 mmol) at room temperature. After 16-hour
stirring, solvent was removed in vacuo, the residue purified by MPLC
(gradient Hex to EtOAc) to give 5-bromo-4-methylthiophene-2-
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1H NMR (CDCl3) d 9.60 (brs, 1H),
7.56 (s, 1H), and 2.22 (s, 3H);
13C NMR (CDCl3) d 166.92, 139.17,
136.66, 131.62, 119.99, and 15.49. The resulting acid was
converted to 16 (82%) following the literature procedure [49].
1H
NMR (CDCl3) d 7.38 (s, 1H), 2.18 (s, 3H), and 1.55 (s, 9H);
13C
NMR (CDCl3) d 160.90, 138.42, 134.71, 134.35, 116.95, 82.33,
28.41, and 15.46.
tert-Butyl 5-bromo-4-formylthiophene-2-carboxylate (17). Com-
pound 16 (0.80 g, 2.89 mmol) and a catalytic amount of AIBN
were dissolved in benzene (10 mL), followed by NBS (0.51 g,
2.89 mmol) at room temperature. The resulting mixture was
heated to reflux for 15 hours. Solvent was removed in vacuo, the
residue purified by MPLC (gradient Hex to EtOAc) to give an
inseparable mixture of the starting material/desired product/
dibromination by-product at a ratio of 2:7:1 in total 75% yield.
1H
NMR (CDCl3) d 7.58 (s, 1H), 4.40 (s, 2H), 1.55 (s, 9H). The
mixture (1.68 g) was subjected to the Hass-Bender reaction [50].
MPLC purification (gradient Hex to EtOAc) afforded 17 as a pale
yellow solid (0.91 g, 66%).
1H NMR (CDCl3) d 9.90 (s, 1H), 7.87
(s, 1H), and 1.56 (s, 9H).
(E)-tert-Butyl 5-bromo-4-(3-ethoxy-3-oxoprop-1-enyl)thiophene-
2-carboxylate (18). Aldehyde 17 (0.91 g, 3.13 mmol) was dissolved
in benzene (12 mL), followed by (ethoxycarbonylmethylene)tri-
phenylphosphorane (2.18 g, 6.26 mmol), and then heated at 80uC
for 19 hours. Solvent was evaporated, and MPLC purification of
the residue (gradient Hex to EtOAc) afforded 18 as a viscous oil
(1.13 g, quantitative).
1H NMR (CDCl3) d 7.71 (s, 1H), 7.60 (d,
J=16.0 Hz, 1H), 6.34 (d, J=16.0 Hz, 1H), 4.27 (q, J=7.1 Hz,
2H), 1.56 (s, 9H), and 1.34 (t, J=7.1 Hz, 3H).
(E)-tert-Butyl 4-(3-ethoxy-3-oxoprop-1-enyl)-5-(3-hydroxy-3,3-
diphenylprop-1-ynyl)thiophene-2-carboxylate (19). To a stirred
mixture of compound 18 (0.34 g, 0.94 mmol), 1,1-diphenylprop-
2-yn-1-ol (0.39 g, 1.87 mmol), CuI (25 mg, 0.13 mmol), and
PdCl2(PPh3)2 (46 mg, 0.07 mmol) in DMF (7 mL) was added Et3N
(1.25 mL) at room temperature. After 17-hour stirring, H2O
(5 mL) was added, extracted with EtOAc (3610 mL), the extracts
were combined, washed with brine, dried over MgSO4, filtered,
concentrated, and purified by MPLC (gradient Hex to EtOAc) to
give 19 in a quantitative yield.
1H NMR (CDCl3) d 7.73 (s and d,
for d, J=15.9 Hz, 1H each), 7.64 (d, J=7.6 Hz, 4H), 7.38–7.34
(m, 4H), 7.29 (t, J=7.2 Hz, 2H), 6.37 (d, J=15.9 Hz), 4.21 (q,
J=7.2 Hz, 2H), 1.56 (s, 9H), and 1.28 (t, J=7.2 Hz, 3H);
13C
NMR (CDCl3) d 166.96, 160.51, 144.42, 140.75, 136.45, 135.92,
130.05, 128.84, 128.70, 128.65, 128.57, 128.22, 126.27, 120.51,
83.16, 78.52, 75.33, 60.92, 28.36, 21.29, and 14.52.
tert-Butyl 4-(3-ethoxy-3-oxopropyl)-5-(3-hydroxy-3,3-diphenyl-
propyl)thiophene-2-carboxylate (20). To a stirred solution of 19
(0.46 g, 0.94 mmol) in MeOH (15 mL) Raney-Ni (1.0 mL as
MeOH slurry) was added, and the stirring was continued under a
balloon of hydrogen for 17 hours. The metal catalyst was removed
with a magnet, the catalyst was washed with MeOH. The
washings and the aliquot were combined, concentrated in vacuo,
purified by MPLC (gradient Hex to EtOAc) to give 20 as an oil
(0.42 g, 91%).
1H NMR (CDCl3) d 7.45 (d, J=7.8 Hz, 4H), 7.41
(s, 1H), 7.34–7.30 (m, 4H), 7.23 (t, J=7.2 Hz, 2H), 4.09 (q,
J=7.2 Hz, 2H), 2.77–2.70 (m, 4H), 2.62–2.58 (m, 3H), 2.47 (t,
J=7.5 Hz, 2H), 1.54 (s, 9H), and 1.21 (t, J=7.2 Hz, 3H);
13C
NMR (CDCl3) d 172.93, 161.79, 147.52, 146.65, 136.99, 134.24,
131.66, 128.56, 127.30, 126.15, 81.65, 78.03, 60.82, 44.10, 35.05,
28.47, 23.36, 23.08, and 14.41.
5-(3,3-Diphenylallyl)-4-(3-ethoxy-3-oxopropyl)thiophene-2-car-
boxylic acid (21). Intermediate 20 (0.38 g, 0.76 mmol) and p-TSA
hydrate (0.15 g, 0.76 mmol) were dissolved in benzene (10 mL)
at room temperature. The resulting mixture was heated at
70–75uC for 40 minutes. The reaction mixture was washed with
water (10 mL), dried over MgSO4, concentrated, and the residue
was purified by MPLC (gradient Hex to EtOAc) to give 21 as an
oily residue (0.23 g, 65%).
1H NMR (CDCl3) d 10.80 (brs, 1H),
7.65 (s, 1H), 7.42–7.35 (m, 4H), 7.29–7.24 (m, 6H), 6.21 (t,
J=7.4 Hz, 1H), 4.11 (q, J=7.2 Hz, 2H), 3.61 (d, J=7.4Hz,
2H), 2.78 (t, J=7.6Hz,2H),2.51(t,J=7 . 6H z ,2 H ) ,a n d1 . 2 2
(t, J=7.2Hz,3H);
13CN M R( C D C l 3) d 172.72, 167.85, 149.21,
144.52, 141.95, 139.35, 137.59, 136.58, 129.94, 128.72, 128.46,
127.77, 127.68, 124.99, 60.88, 34.83, 29.21, 23.52, and 14.43.
Ethyl 3-(5-(bis(10-(1,3-dioxoisoindolin-2-yl)decyl)carbamoyl)-2-
(3,3-diphenylallyl)thiophen-3-yl)propanoate (22). To a stirred
mixture of 21 (109 mg, 0.26 mmol), 14z (152 mg, 0.26 mmol),
BOP (115 mg, 0.26 mmol), and HOBt (35 mg, 0.26 mmol) in dry
DMF (3 mL) was added NMM (34.2 mL, 0.31 mmol) at room
temperature. After 13 hours stirring, H2O (5 mL) was added,
extracted with EtOAc (365 mL). The extracts were combined,
washed with brine, dried over MgSO4, filtered, concentrated, and
then purified by MPLC (gradient Hex to EtOAc) to give 22 as an
oil (187 mg, 73%).
1H NMR (CDCl3) d 7.80–7.78 (m, 4H),
7.67–7.65 (m, 4H), 7.37–7.29 (m, 3H), 7.24–7.17 (m, 7H), 7.05 (s,
1H), 6.15 (t, J=7.4 Hz, 1H), 4.06 (q, J=7.2 Hz, 2H), 3.63 (t,
J=7.1 Hz, 4H), 3.52 (d, J=7.5 Hz, 2H), 3.40–3.39 (m, 4H), 2.71
(t, J=7.5 Hz, 2H), 2.44 (t, J=7.5 Hz, 2H), 1.62–1.59 (m, 8H),
and 1.23–1.51 (m, 24H);
13C NMR (CDCl3) d 172.72, 168.62,
164.20, 143.60, 142.11, 142.05, 139.49, 135.75, 134.77, 134.86,
134.06, 132.36, 130.48, 130.00, 128.60, 128.36, 127.61, 127.55,
125.96, 123.33, 60.67, 38.22, 35.07, 29.69, 29.61, 29.57, 29.34,
28.80, 28.58, 27.03, 23.57, and 14.44.
Ethyl 3-(5-(bis(10-(1,3-dioxoisoindolin-2-yl)decyl)carbamoyl)-2-
(3,3-diphenylpropyl)thiophen-3-yl)propanoate (23). To a stirred
solution of compound 15 (187 mg, 0.19 mmol) in EtOAc (5 mL)
was added 10% Pd-C (40 mg). The resulting suspension was
stirred under a balloon of hydrogen for 20 hours at room
temperature. The catalyst was removed by filtration through Celite,
and concentration of the filtrate gave 23 (171 mg, 91%).
1HN M R
(CDCl3) d 7.84–7.81 (m, 4H), 7.70–7.68 (m, 4H), 7.30–7.23 (m,
8H), 7.18–7.15 (m, 2H), 7.04 (s, 1H), 4.07 (q, J=7.2 Hz, 2H), 3.98
(t, J=7.8 Hz, 1H), 3.66 (t, J=7.2 Hz, 4H), 3.44–3.40 (m, 4H),
2.71–2.63 (m, 4H), 2.44–2.35 (m, 4H), 1.65–1.61 (m, 8H), and
1.54–1.19 (m, 27H);
13C NMR (CDCl3) d 172.80, 168.71, 164.26,
144.43, 142.95, 135.92, 134.33, 134.08, 132.38, 130.41, 128.81,
128.62, 128.04, 126.58, 123.38, 60.69, 50.68, 38.27, 37.49, 35.17,
29.73, 29.64, 29.60, 29.37, 28.83, 27.07, 26.33, 23.47, and
14.46.
N,N-Bis(10-aminodecyl)-5-(3,3-diphenylpropyl)-4-(3-(hydroxya-
mino)-3-oxopropyl)thiophene-2-carboxamide (8). A stirred solu-
tion of 23 (171 mg, 0.17 mmol) in MeOH:THF (2 mL each)
containing 50% aqueous NH2OH (1 mL) and a catalytic amount
(two crystals) of KCN was heated at 65uC for 24 hours. The
resulting solution was filtered through Celite, concentrated, re-
dissolved in MeOH, and purified by HPLC (eluting time: 20
minutes) to give of 8N2TFA (23 mg, 14%). Both semi-preparative
and analytical HPLC retention times of 8N2TFA are 14.83 minutes
(see Figure S7 for chromatograms of 8N2TFA before and after the
HPLC purification).
1H NMR (CD3OD) d 7.28–7.27 (m, 8H),
7.20–7.15 (m, 2H), 7.11 (s, 1H), 4.00 (t, J=7.8 Hz, 1H), 3.50–3.40
(brs, 4H), 2.88 (t, J=7.2 Hz, 4H), 2.74 (t, J=7.6 Hz, 2H), 2.67 (t,
J=7.2 Hz, 2H), 2.39 (q, J=7.6 Hz, 2H), 2.23 (t, J=7.2 Hz, 2H),
1.70–1.52, (m, 8H), and 1.40–1.20 (m, 24H);
13C NMR (CD3OD)
d 170.24, 165.32, 160.34 (q), 144.59, 143.32, 136.41, 133.15,
130.77, 128.44, 128.24, 128.18, 127.73, 126.24, 125.90, 116.58
(q), 50.59, 39.54, 37.44, 33.48, 29.32, 29.20, 29.15, 28.98, 27.36,
26.58, 26.23, 25.82, and 23.61; IR cm
21 3060, 3028, 2921, 2852,
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C43H66N4O3S[ M +H
+] 719.4928, found 719.4956.
Synthesis of analog 9. Ethyl 2-(2-Bromothiophen-3-
yl)acetate (25). To a solution of 24 (20.30 g, 119.25 mmol) in
THF (150 mL) was added NBS (21.23 g, 119.25 mmol) over a
period of 5 hours at 0uC, and then the mixture was warmed up to
room temperature, stirring continued for 24 hours. The solvent
was removed in vacuo, and the residue was dissolved in EtOAc
(150 mL), washed with brine (4630 mL). The organic layer was
dried over MgSO4, filtered, and concentrated in vacuo. MPLC
purification (Hex:EtOAc/5:1) of the residue gave 25 as a colorless
oil (24.00 g, 81%).
1H NMR (CDCl3) d 7.23 (d, J=5.4 Hz, 1H),
6.93 (d, J=5.4 Hz, 1H), 4.17 (q, J=7.2 Hz, 2H), 3.61 (s, 2H), and
1.27 (t, J=7.2 Hz, 3H);
13C NMR (CDCl3) d 170.37, 133.84,
128.90, 125.93, 111.78, 61.32, 35.30, and 14.43.
Ethyl 2-(2-bromo-5-(chlorocarbonyl)thiophen-3-yl)acetate (26).
A solution of oxalyl chloride (2.00 g, 16 mmol) in CH2Cl2 (3 mL)
was added dropwise into a suspension of AlCl3 (1.064 g, 8 mmol)
in CH2Cl2 (6 mL) at 0uC. After the mixture was stirred for 1 hour,
a solution of 25 (1.00 g, 4 mmol) in CH2Cl2 (2 mL) was added
into the mixture during a period of 1 hour at 0uC. The mixture
was allowed to warm up to room temperature and stirred for
additional 3 hours. The reaction mixture was poured into ice cold
H2O (20 mL) and extracted with Et2O (100 mL). The organic
layer was washed with brine (3615 mL), dried over MgSO4, and
concentrated in vacuo. MPLC purification (Hex:EtOAc/20:1) of
the residue gave 26 as a colorless oil (682 mg, 54%).
1H NMR
(CDCl3) d 7.82 (s, 1H), 4.19 (q, J=7.2 Hz, 2H), 3.64 (s, 2H), and
1.28 (t, J=7.2 Hz, 3H);
13C NMR (CDCl3) d 169.30, 159.01,
139.01, 136.64, 136.46, 126.06, 61.79, 35.18, and 14.40.
4-Methoxybenzyl 5-bromo-4-(2-ethoxy-2-oxoethyl)thiophene-2-
carboxylate (27). To a solution of 4-methoxybenzyl alcohol
(220 mL, 1.75 mmol) and Et3N (244 mL, 1.75 mmol) in CH2Cl2
(12 mL) was added dropwise a solution of 26 (367 mg, 1.17 mmol)
in CH2Cl2 (3 mL) at room temperature. After the mixture was
stirred for 1 hour at room temperature, it was poured into H2O
(20 mL) and extracted with Et2O (50 mL). The organic layer was
washed with brine (2610 mL), dried over MgSO4, and concen-
trated in vacuo. MPLC purification (Hex:EtOAc/8:1) of the residue
gave 27 as a white solid (400 mg, 82%).
1H NMR (CDCl3) d 7.61
(s, 1H), 7.34 (d, J=8.4 Hz, 4H), 6.90 (d, J=8.4 Hz, 2H), 5.23 (s,
2H), 4.16 (q, J=7.2 Hz, 2H), 3.80 (s, 3H), 3.59 (s, 2H), and 1.26
(t, J=7.2 Hz, 3H);
13C NMR (CDCl3) d 169.76, 161.30, 159.99,
135.14, 134.73, 133.55, 130.45, 127.80, 119.89, 114.22, 67.14,
61.56, 55.53, 35.28, and 14.40.
4-Methoxybenzyl 4-(2-ethoxy-2-oxoethyl)-5-(3-hydroxy-3,3-
diphenylprop-1-ynyl)thiophene-2-carboxylate (28). CuI (7 mg,
0.037 mmol) was added into a mixture of 27 (214 mg, 0.51 mmol),
PdCl2(PPh3)2 (20 mg, 0.028 mmol), Et3N (1.046 g, 10.36 mmol)
and 1,1-diphenylprop-2-yn-1-ol (237 mg, 1.14 mmol) in anhy-
drous DMF (4 mL). The mixture was stirred at room temperature
for 2 days. The mixture was poured into H2O and extracted with
Et2O (100 mL). The organic layer was washed with brine
(4620 mL), dried over MgSO4, and concentrated in vacuo. MPLC
purification (Hex:EtOAc/6:1) of the residue gave 28 as a brown oil
(206 mg, 74%).
1H NMR (CDCl3) d 7.67 (s, 1H), 7.62 (d,
J=7.6 Hz, 4H), 7.3827.25 (m, 8H), 6.90 (d, J=8.8 Hz, 2H),
5.24 (s, 2H), 4.10 (q, J=7.0 Hz, 2H), 3.81 (s, 3H), 3.67 (s, 2H), and
1.20 (t, J=7.2 Hz, 3H);
13C NMR (CDCl3) d 170.18, 161.56,
159.98, 144.60, 139.49, 134.65, 133.54, 130.46, 128.64, 128.19,
127.83, 126.73, 126.24, 114.23, 101.51, 78.92, 75.28, 67.21, 61.54,
55.54, 35.33, and 14.37.
4-(2-Ethoxy-2-oxoethyl)-5-(3-hydroxy-3,3-diphenylpropyl)thio-
phene-2-carboxylic acid (29). To a solution of 28 (76 mg,
0.14 mmol) in dry MeOH (4 mL) was added 10% Pd-C
(38 mg). The mixture was stirred under a balloon of hydrogen
for 2 days at room temperature and filtered through Celite.
Concentration of the filtrate in vacuo gave 29 as a colorless oil
(50 mg, 83%).
1H NMR (CDCl3) d 7 . 6 6( s ,1 H ) ,7 . 4 4( d ,
J= 7 . 6H z ,4 H ) ,7 . 3 3( t ,J= 7 . 6H z ,4 H ) ,7 . 2 8 27.22 (m, 2H),
4.11 (q, J=7.2 Hz, 2H), 3.44 (s, 2H), 2.8222.75 (m, 2H),
2.6722.60 (m, 2H), and 1.22 (t, J=7.2Hz, 3H);
13CN M R
(CDCl3) d 170.97, 167.28, 151.87, 146.49, 137.33, 131.03,
128.88, 128.60, 128.01, 127.37, 126.71, 126.14, 78.05, 61.50,
43.73, 34.09, 29.95, 23.52, and 14.37.
5-(3,3-Diphenylallyl)-4-(2-ethoxy-2-oxoethyl)thiophene-2-car-
boxylic acid (30). To a solution of 29 ( 2 2m g ,0 . 0 5 2m m o l )i n
benzene (6 mL) was added p-TSA hydrate (9 mg, 0.052 mmol).
After the mixture was stirred at 70uC for 1 hour, it was poured
into H2O (20 mL) and extracted with Et2O( 5 0m L ) .T h eo r g a n i c
layer was washed with brine (2615 mL), dried over MgSO4,a n d
concentrated in vacuo to give 30 as a colorless oil (22 mg,
quantitative yield).
1H NMR (CDCl3) d 7 . 7 1( s ,1 H ) ,7 . 4 4 27.20
(m, 10H), 6.20 (t, J=7 . 4H z ,1 H ) ,4 . 0 9( q ,J=7 . 2H z ,2 H ) ,3 . 6 0
(d, J=7.2 Hz, 2H), 3.46 (s, 2H), and 1.19 (t, J=7.2 Hz, 3H);
13C
NMR (CDCl3) d 170.63, 167.35, 150.56, 144.62, 141.88, 139.31,
137.52, 131.02, 129.93, 128.73, 128.44, 127.80, 127.68, 124.68,
104.60, 61.42, 34.13, 29.40, and 14.35.
5-(3,3-Diphenylpropyl)-4-(2-ethoxy-2-oxoethyl)thiophene-2-car-
boxylic acid (31). To a solution of 30 (22 mg, 0.054 mmol) in dry
MeOH (5 mL) and EtOAc (1 mL) was added 10% Pd-C (4 mg).
The mixture was stirred under a balloon of hydrogen for 12 hours
at room temperature and filtered through Celite. Concentration of
the filtrate in vacuo gave 31 as a colorless oil (22 mg, quantitative
yield).
1H NMR (CDCl3) d 7.69 (s, 1H), 7.3227.16 (m, 10H), 4.10
(q, J=7.2 Hz, 2H), 3.98 (t, J=8.0 Hz, 1H), 3.37 (s, 2H), 2.75 (t,
J=7.8 Hz, 2H), 2.43 (q, J=8.0 Hz, 2H), and 1.21 (t, J=7.2 Hz,
3H);
13C NMR (CDCl3) d 170.69, 167.27, 151.15, 144.20, 137.27,
131.21, 129.05, 128.88, 128.02, 126.72, 61.39, 50.75, 37.13,
34.05, 27.20, and 14.37.
Ethyl 2-(5-(bis(10-(1,3-dioxoisoindolin-2-yl)decyl)carbamoyl)-2-
(3,3-diphenylpropyl)thiophen-3-yl)acetate (32). A mixture of 31
(22 mg, 0.054 mmol), BOP (36 mg, 0.081 mmol), NMM (8 mg,
0.081 mmol), HOBt (11 mg, 0.081 mmol), and 14z (47 mg,
0.081 mmol) in anhydrous DMF (4 mL) was stirred at room
temperature under N2 for ,24 hours. When the reaction was over
by TLC monitoring, the mixture was poured into H2O (10 mL)
and then extracted with Et2O (70 mL). The organic layer was
washed with brine (3610 mL), dried over MgSO4, and concen-
trated in vacuo. MPLC purification (Hex/EtOAc 4:1) of the residue
gave 32 as a yellow amorphous solid (32 mg, 74% based on
recovery of starting material).
1H NMR (CDCl3) d 7.8627.80 (m,
4H), 7.7327.68 (m, 4H), 7.3127.15 (m, 10H), 7.13 (s, 1H), 4.08
(q, J=7.2 Hz, 2H), 3.98 (t, J=8.0 Hz, 1H), 3.67 (t, J=7.4 Hz,
4H), 3.44 (brt, 4H), 3.33 (s, 2H), 2.70 (t, J=7.6 Hz, 2H), 2.40 (q,
J=7.6 Hz, 2H), 1.7021.57 (m, 8H), 1.3621.23 (m, 24H), and
1.20 (t, J=7.2 Hz, 3H);
13C NMR (CDCl3) d 170.91, 168.70,
164.02, 144.60, 144.40, 134.69, 134.08, 132.39, 130.87, 129.36,
128.80, 128.04, 126.59, 123.38, 61.15, 50.66, 38.27, 37.32, 34.18,
29.72, 29.63, 29.58, 29.37, 28.82, 27.06, 26.54, and 14.40.
N, N-Bis(10-aminodecyl)-5-(3,3-diphenylpropyl)-4-(2-(hydroxya-
mino)-2-oxoethyl)thiophene-2-carboxamide (9). To a stirred
solution of 32 (18 mg, 0.018 mmol) in THF/MeOH (1.5 mL/
1.5 mL), 1 mL of 50% aqueous NH2OH was added, followed by
catalytic amount (two crystals) of KCN. The resulting mixture was
stirred for 23 hours at room temperature, and then filtered
through a short Celite column. HPLC purification (eluting time:
30 minutes) of the filtrate gave 9N2TFA as a white amorphous solid
Small-Molecule BoNTA Inhibitor
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HPLC retention times of 9N2TFA are 17.70 and 15.07 minutes,
respectively (see Figure S8 for chromatograms of 9N2TFA before
and after the HPLC purification).
1H NMR (DMSO-d6) d 10.62
(s, 1H), 7.69 (brs, 7H), 7.3527.10 (m, 11H), 3.98 (t, J=7.8 Hz,
1H), 3.37 (brs, 4H), 3.10 (s, 2H), 2.72 (m, 4H), 2.64 (t, J=7.6 Hz,
2H), 2.33 (q, J=7.2 Hz, 2H), 1.6021.40 (m, 8H), 1.3021.15 (m,
24H);
13C NMR (DMSO-d6) d 167.04, 163.29, 158.66 (q), 145.18,
143.86, 134.23, 132.01, 131.52, 129.21, 128.26, 126.91, 50.68,
39.50, 39.40, 37.26, 32.69, 29.57, 29.47, 29.44, 29.19, 27.68,
27.62, 26.89, and 26.44; IR cm
21 2934, 2852, 1683, 1589, 1205,
and 1136; HRMS-ESI calculated for C42H64N4O3S[ M +H
+]
705.4772, found 705.4761.
Synthesis of analog 10b. Methyl 4-formyl-5-iodo-1H-
pyrrole-2-carboxylate (34). To a stirred solution of 33 (3.40 g,
22.2 mmol) in CHCl3 (20 mL) at 0uC was added CF3CO2Ag
(5.40 g, 24.4 mmol) followed by adding I2 in three portions each
with 2.07 g (8.13 mmol) of the material. The resulting mixture
was stirred for 16 hours in dark at room temperature. The reaction
mixture was filtered through Celite and the filtrate was washed with
saturated aqueoussolutionofNa2S2O3.Theorganiclayerwasdried
over anhydrous MgSO4, filtered and concentrated in vacuo. MPLC
purification (CH2Cl2:Et2O/95:5) of the residue gave 34 as a white
solid (1.90 g,29%).Alongwith34,twominorcompoundsmethyl4-
formyl-5-iodo-1H-pyrrole-2-carboxylate, methyl 4-formyl-3,5-
diiodo-1H-pyrrole-2-carboxylate and the starting material 33
were also isolated.
1H NMR (DMSO-d6) d 13.31 (brs, 1H), 9.52
(s, 1H), 7.04 (s, 1H), and 3.76 (s, 3H);
13C NMR (DMSO-d6) d
187.13, 160.36, 128.78, 127.79, 115.58, 87.40, and 52.42.
Methyl1-benzyl-4-formyl-5-iodo-1H-pyrrole-2-carboxylate(35x).
To a stirred solution of 34 (0.72 g, 2.56 mmol) in acetone (20 mL)
was added K2CO3 (0.71 g, 5.12 mmol). The resulting mixture was
stirred for 30 minutes at room temperature. Benzyl bromide
(0.46 mL, 3.84 mmol) was added dropwise to the reaction mixture
and was refluxed for 16 hours. The reaction mixture was cooled to
room temperature, concentrated and partitioned twice between
ethyl acetate (10 mL) and water (10 mL). The aqueous layer was
washed with EtOAc (10 mL).The combined organic layer wasdried
over anhydrous MgSO4, filtered and then concentrated in vacuo.
MPLC purification (Hex:EtOAc/80:20) of the residue gave 35x as a
white solid (0.85 g, 90%).
1H NMR (CDCl3) d 9.66 (s, 1H), 7.50 (s,
1H), 7.25–7.18 (m, 3H), 6.98 (d, J=7.6 Hz, 2H), 5.75 (s, 2H), and
3.72 (s, 3H);
13C NMR (CDCl3) d 186.98, 160.33, 136.43, 128.97,
128.22, 127.84, 127.10, 126.59, 119.32, 92.81, 52.81, and 52.11.
Methyl 1-benzyl-4-formyl-5-(3-hydroxy-3,3-diphenylprop-1-
ynyl)-1H-pyrrole-2-carboxylate (36x). A solution of 35x (0.47 g,
1.26 mmol), 1,1-diphenylprop-2-yn-1-ol (0.66 g, 3.15 mmol), CuI
(0.048 g, 0.25 mmol), Pd(PPh3)2Cl2 (0.18 g, 0.3 mmol), PPh3
(0.066 g, 0.3 mmol), and Et3N (4 mL) in anhydrous DMF
(4 mL) was stirred for 16 hours at 70uC under N2 atmosphere.
The reaction mixture was partitioned between water and EtOAc.
The combined organic layer was dried over MgSO4, filtered and
concentrated in vacuo. MPLC purification (Hex:EtOAc/80:20) of
the residue gave 36x as a pale yellow solid (0.49 g, 87%).
1H
NMR (CDCl3) d 9.88 (s, 1H), 7.52–7.50 (m, 4H), 7.36 (s, 1H),
7.30–7.24 (m, 9H), 7.08–7.02 (m, 2H), 5.69 (s, 2H), 3.80 (s, 3H),
and 3.65 (s, 1H);
13C NMR (CDCl3) d 185.16, 160.72, 144.07,
136.84, 128.91, 128.72, 128.33, 127.91, 127.79, 127.05, 126.23,
124.96, 116.97, 103.35, 75.37, 75.27, 52.15, and 50.38.
1H-
13C
HMBC (CDCl3): there is a correlation between the pyrrole proton
and the carbonyl carbon of the methyl ester, and there is no
correlation between the pyrrole proton and the benzylic carbon.
1-Benzyl-4-formyl-5-(3-hydroxy-3,3-diphenylprop-1-ynyl)-1H-pyr-
role-2-carboxylicacid(37x). Toa solutionof 36x(0.49 g, 1.09 mmol)
in MeOH (20 mL) and water (6 mL) was added KOH (0.18 g,
3.27 mmol) and stirred at 60uC for 2 hours. The solvent was
removed invacuo. The residue obtained was acidified with 2 N HCl to
pH 2–3 and extracted with EtOAc (3615 mL). The combined
organic layer was dried over MgSO4, filtered and then concentrated
in vacuo to give 37x as a light brown solid. The crude product was
subjected to the next reaction without further purification.
1HN M R
(CDCl3) d 9.82 (s, 1H), 7.52–7.50 (m, 4H), 7.45 (s, 1H), 7.30–7.18 (m,
9H), 7.06–6.99 (m, 2H), and 5.64 (s, 2H).
1-Benzyl-N,N-bis(6-(1,3-dioxoisoindolin-2-yl)hexyl)-4-formyl-5-
(3-hydroxy-3,3-diphenylprop-1-ynyl))-1H-pyrrole-2-carboxamide
(38x). A solution of 37x (0.35 g, 0.81 mmol), 14x (0.46 g,
0.97 mmol), BOP (0.73 g, 1.61 mmol), HOBt (0.22 g, 1.61 mmol)
in anhydrous DMF (3 mL) and NMM (2 mL) was stirred at room
temperature for 16 hours. The reaction mixture was partitioned
between water and CH2Cl2 (20 mL). The organic layer was dried
over MgSO4, filtered and concentrated in vacuo. MPLC purification
(Hex:EtOAc/40:60) of the residue gave 38x as a pale yellow oil.
(0.30 g, 41%).
1H NMR (CDCl3) d 9.86 (s, 1H), 7.82–7.75 (m, 4H),
7.70–7.62 (m, 4H), 7.56–7.54 (m, 4H), 7.27–7.21 (m, 6H), 7.15–7.14
(m, 3H), 7.02–6.98 (m, 2H), 6.58 (s, 1H), 5.34 (s, 2H), 3.68–3.52 (m,
4H), 3.28–3.18 (m, 2H), 3.04–2.94 (m, 2H), 1.68–1.59 (m, 2H),
1.58–1.46 (m, 2H), 1.42–1.27 (m, 6H), 1.18–1.04 (m, 4H), and 1.02–
0.94 (m, 2H);
13C NMR (CDCl3) d 185.34, 168.68, 162.62, 144.57,
136.84, 134.15, 132.26, 129.37, 128.87, 128.61, 128.11, 127.79,
127.29,126.20,125.18, 123.42, 109.14, 102.74, 75.31, 75.10,49.57,
45.39, 37.96, 28.57, 27.13, 26.73, 26.48, and 26.28.
(E)-Ethyl 3-(1-benzyl-5-bis(6-(1,3-dioxoisoindolin-2-yl)hexyl)
carbamoyl)-2-(3-hydroxy-3,3-diphenylprop-1-ynyl))-1H-pyrrol-3-
yl)acrylate (39x). To a stirred solution of 38x (0.33 g, 0.37 mmol)
in benzene (20 mL) was added (ethoxycarbonylmethylene)triphe-
nylphosphorane (0.35 g, 0.92 mmol). The resulting mixture was
stirred under reflux for 16 hours. The reaction mixture was
cooled to room temperature and the solvent was removed in vacuo.
MPLC purification (Hex:EtOAc/50:50) of the residue gave 39x
as a pale yellow oil (0.30 g, 85%).
1H NMR (CDCl3) d 7.86–7.79
(m, 4H), 7.72–7.65 (m, 5H), 7.57–7.55 (m, 4H), 7.31–7.22 (m,
6H), 7.20–7.15 (m, 3H), 7.06–6.98 (m, 2H), 6.42 (s, 1H), 6.25 (d,
J=15.6 Hz, 1H), 5.33 (s, 2H), 4.18 (q, J=7 . 2H z ,2 H ) ,3 . 7 0 – 3 . 5 8
(m, 4H), 3.44 (s, 1H), 3.32–3.02 (m, 4H), 1.70–1.50 (m, 4H), and
1.49–1.12 (m, 15H);
13C NMR (CDCl3) d 168.68, 167.65, 163.07,
144.63, 137.59, 136.76, 134.14, 132.32, 129.43, 128.98, 128.79,
128.66, 128.61, 128.06, 127.86, 127.77, 127.57, 126.24, 123.97,
123.42, 119.74, 115.04, 108.54, 102.26, 77.18, 75.34, 64.61,
60.36, 49.60, 38.00, 30.86, 28.64, 26.75, and 14.44.
Ethyl 3-(1-benzyl-5-(bis(6-(1,3-dioxoisoindolin-2-yl)hexyl)
carbamoyl)-2-(3-hydroxy-3,3-diphenylpropyl)-1H-pyrrol-3-yl)-
propanoate (40x). To a stirred solution of 39x (0.15 g,
0.16 mmol) in EtOAc (20 mL) was added 10% dry Pd-C
(0.015 g). The resulting mixture was stirred at room tempera-
ture for 48 hours under a balloon of hydrogen. The reaction
m i x t u r ew a sf i l t e r e dt h r o u g hC e l i t ea n dt h ef i l t r a t ew a s
concentrated to give 40x as a colorless oil. The crude product
was subjected to the next reaction without further purification.
1H NMR of the crude product is as follows.
1HN M R( C D C l 3) d
7.77–7.75 (m, 4H), 7.64–7.62 (m, 4H), 7.27–7.06 (m, 13H), 6.71
(d, J=7.2 Hz, 2H), 6.05 (s, 1H), 5.09 (s, 2H), 3.98 (q,
J=6.8 Hz, 2H), 3.57 (t, J=7.2 Hz, 4H), 3.19 (t, J=6.8Hz,
4H), 2.56 (t, J=7.6 Hz, 2H), 2.41–2.37 (m, 4H), 2.26–2.24 (m,
2H), 1.56–1.53 (m, 4H), and 1.30–1.11 (m, 15H).
N,N-Bis(6-aminohexyl)-1-benzyl-5-(3-(hydroxy-3,3-diphenylpro-
pyl)-4-(3-hydroxyamino)-3-oxopropyl))-1H-pyrrole-2-carboxamide
(10b). To a stirred solution of 40x (0.15 g, 0.16 mmol) in
MeOH:THF (3 mL each) was added 50% aqueous hydroxyl-
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resulting mixture was stirred at 35uC for 24 hours. After the
solvent was removed in vacuo, the residue was subjected to HPLC
purification (eluting time: 45 minutes). The eluent from HPLC was
concentrated in vacuo at room temperature to remove the organic
solvents. The resulting aqueous solution was lyophilized to give
10bN2TFA as a white sticky solid (0.032 g, 22%). The semi-
preparative and analytical HPLC retention times of 10bN2TFA
are 18.27 and 11.50 minutes, respectively (see Figure S9 for
chromatograms of 10bN2TFA before and after the HPLC
purification).
1H NMR (DMSO-d6) d 10.40 (brs, 1H), 7.70 (brs,
6H), 7.42–7.40 (m, 4H), 7.26–7.12 (m, 9H), 6.68 (d, J=7.2 Hz,
2H), 6.10 (s, 1H), 5.15 (s, 2H), 3.26–3.18 (m, 4H), 3.14 (s, 1H),
2.74–2.68 (m, 4H), 2.45 (overlapped with DMSO-d6, 2H),
2.34–2.28 (m, 4H), 2.17 (t, J=7.2 Hz, 2H), 1.49–1.41 (m, 4H),
1.36–1.25 (m, 4H), 1.24–1.16 (m, 4H), and 1.14–1.02 (m, 4H);
13C
NMR (DMSO-d6) d 169.44, 164.17, 158.86 (q), 148.59, 140.07,
133.78, 128.93, 128.54, 127.44, 126.86, 126.48, 126.28, 124.81,
118.30, 115.50 (q), 111.50, 76.72, 47.24, 42.30, 39.40, 34.50,
27.60, 26.41, 26.20, 21.75, and 19.05; IR cm
21 3407, 3089, 3060,
3032, 2946, 2860, 1683, 1597, 1495, 1209, and 1140; HRMS-ESI
calculated for C42H57N5O4 [M+H
+] 696.4483, found 696.4510.
Synthesis of analog 11. Methyl 4-formyl-5-iodo-1-methyl-
1H-pyrrole-2-carboxylate (35y). To a stirred solution of 34
(0.30 g, 1.08 mmol) in acetone (10 mL) was added K2CO3
(0.30 g, 2.15 mmol). The resulting mixture was stirred for 30
minutes at room temperature. Methyl iodide (0.23 g, 1.62 mmol)
was added drop wise to the reaction mixture and was refluxed for
16 hours. The reaction mixture was cooled to room temperature,
concentrated and partitioned between ethyl acetate (10 mL) and
water (10 mL). The aqueous layer was washed with EtOAc
(2610 mL). The combined organic layer was dried over
anhydrous MgSO4, filtered and concentrated in vacuo. MPLC
purification (Hex:EtOAc/80:20) of the residue gave 35y as a white
solid (0.20 g, 63%).
1H NMR (CDCl3) d 9.60 (s, 1H), 7.39 (s, 1H),
3.98 (s, 3H), and 3.80 (s, 3H);
13C NMR (CDCl3) d 186.84,
160.71, 128.32, 126.61, 118.76, 92.60, 52.05, and 38.00.
Methyl 4-formyl-5-(3-hydroxy-3,3-diphenylprop-1-ynyl)-1-meth-
yl-1H-pyrrole-2-carboxylate (36y). A solution of 35y (0.20 g,
0.68 mmol), 1,1-diphenylprop-2-yn-1-ol (0.36 g, 1.7 mmol), CuI
(0.025 g, 0.14 mmol), Pd(PPh3)2Cl2 (0.097 g, 0.14 mmol), PPh3
(0.036 g, 0.14 mmol), and Et3N (2 mL) in anhydrous DMF (3 mL)
was stirred for 16 hours at 70uC under N2 atmosphere. The
reaction mixture was partitioned between water (10 mL) and
EtOAc (10 mL). The aqueous layer was washed with EtOAc
(2610 mL). The combined organic layer was dried over MgSO4,
filtered and concentrated in vacuo. MPLC purification (Hex:EtOAc/
70:30) of the residue gave 36y as a pale yellow solid (0.20 g, 79%).
1H NMR (CDCl3) d 9.74 (s, 1H), 7.65–7.63 (m, 4H), 7.35–7.32 (m,
4H), 7.28–7.27 (m, 2H), 7.23 (s, 1H), 4.75 (brs, 1H), 3.87 (s, 3H),
and 3.78 (s, 3H);
13C NMR (CDCl3) d 185.27, 160.96, 144.45,
128.71, 128.28, 127.25, 126.24, 125.29, 116.40, 103.82, 75.19,
74.83, 52.10, and 34.88.
N,N-Bis(7-(1,3-dioxoisoindolin-2-yl)heptyl)-4-formyl-5-(3-droxy-
3,3-diphenylprop-1-ynyl))1-methyl–1H-pyrrole-2-carboxamide (38y).
To a solution of 36y (0.10 g, 0.3 mmol) in MeOH (10 mL) and water
(4 mL) was added KOH (0.06 g, 1.1 mmol) and stirred at 60uCf o r
2h o u r s .T h es o l v e n tw a sr e m o v e din vacuo. The residue obtained was
acidified with 2 N HCl to pH 2–3 and extracted with EtOAc
(10 mL). The aqueous layer was washed with EtOAc (2610 mL). The
combined organic layer was dried over MgSO4,f i l t e r e da n d
concentrated in vacuo to give 37y as a light brown solid. The crude
product was subjected to the next reaction without further
purification. A solution of 37y (0.20 g, 0.6 mmol), 14x (0.34 g,
0.7 mmol), BOP (0.49 g, 1.1 mmol), HOBt (0.15 g, 1.1 mmol) in
anhydrous DMF (3 mL) and NMM (2 mL) was stirred at room
temperature for 16 hours. The reaction mixture was partitioned
between water and dichloromethane (20 mL). The aqueous layer
was washed with dichloromethane (2620 mL). The combined
organic layer was dried over MgSO4, filtered and then concentrated
in vacuo. MPLC purification (Hex:EtOAc/50:50) of the residue gave
38y as a pale yellow oil. (0.30 g, 53%).
1H NMR (CDCl3) d 9.82 (s,
1H), 7.78–7.66 (m, 4H), 7.62–7.58 (m, 8H), 7.27–7.24 (m, 4H),
7.20–7.15 (m, 2H), 6.55 (s, 1H), 5.36 (s, 1H),3.62–3.50 (m, 7H), 3.34
(t, J=6.8 Hz, 4H), 1.66–1.38 (m, 8H), and 1.36–1.04 (m, 12H);
13C
NMR (CDCl3) d 185.15, 168.66, 162.58, 144.92, 134.12, 132.21,
129.97, 128.53, 127.98, 127.28, 126.19, 125.49, 123.35, 108.30,
102.95, 74.90, 74.83, 49.20, 45.20, 38.04, 33.85, 31.60, 28.64, and
26.88.
(E)-Ethyl 3-(5-(bis(7-(1,3-dioxoisoindolin-2-yl)heptyl)carbamoyl)-
2-(3-hydroxy-3,3-diphenylprop-1-ynyl)-1-methyl-1H-pyrrol-3-yl)
acrylate (39y). To a stirred solution of 38y (0.30 g, 0.4 mmol) in
benzene (10 mL) was added (ethoxycarbonylmethylene)triphenyl-
phosphorane (0.31 g, 0.9 mmol). The resulting mixture was stirred
under reflux for 16 hours. The reaction mixture was cooled to
room temperature and the solvent was removed in vacuo. MPLC
purification (Hex:EtOAc/50:50) of the residue gave 39y as a pale
yellow oil (0.22 g, 68%).
1H NMR (CDCl3) d 7.75–7.66 (m, 4H),
7.63–7.57 (m, 9H), 7.28–7.25 (m, 4H), 7.19–7.18 (m, 2H), 6.31 (s,
1H),6.17 (d, J=16.0 Hz, 1H), 4.82 (s, 1H), 4.03 (q, J=6.8 Hz, 2H),
3.62–3.53 (m, 7H), 3.35 (t, J=7.2 Hz, 4H), 1.64–1.48 (m, 8H), and
1.36–1.15 (m, 15H);
13C NMR (CDCl3) d 168.64, 167.64, 163.06,
145.15, 136.84, 134.08, 132.20, 129.58, 128.49, 127.85, 126.25,
123.60,123.32,119.97, 115.60, 108.00, 102.65, 76.56, 75.07,60.26,
49.20, 45.20, 38.03, 33.72, 28.86, 28.63, 26.90, and 14.58.
Ethyl 3-(5-(bis(7-(1,3-dioxoisoindolin-2-yl)heptyl)carbamoyl)-2-
(3-hydroxy-3,3-diphenylpropyl)- 1-methyl-1H-pyrrol-3-yl)propano-
ate(40y). Toa stirred solutionof 39y (0.11 g,0.12 mmol)inEtOAc
(10 mL) was added dry powdered 10% Pd-C (0.01 g). The resulting
mixture was stirred at room temperature for 48 hours under a
balloon of hydrogen. The reaction mixture was filtered through
Celite and the filtrate was concentrated to give 40y as a colorless oil
(0.10 g, 90%). The crude product was subjected to the next reaction
without further purification.
1H NMR (CDCl3) d 7.82–7.80 (m,
4H),7.70–7.68 (m, 4H), 7.46–7.44 (m,4H), 7.32–7.20(m, 6H),6.03
(s, 1H), 4.04 (q, J=6.8 Hz, 2H), 3.63 (t, J=7.2 Hz, 4H), 3.44–3.36
(m, 7H), 2.60–2.52 (m, 4H), 2.46–2.39 (m, 4H), 2.04 (s, 1H),
1.68–1.60 (m, 4H), 1.58–1.49 (m, 4H), and 1.30–1.17 (m, 15H).
N,N-Bis(7-aminoheptyl)-5-(3-hydroxy-3,3-diphenylpropyl)-4-(3-
(hydroxyamino)-3-oxopropyl)-1-methyl-1H-pyrrole-2-carboxa-
mide (11). To a stirred solution of 40y (0.10 g, 0.11 mmol) in
MeOH:THF (4 mL each) was added 50% aqueous hydroxyl-
amine (4 mL) followed by KCN (0.04 g, 0.55 mmol ). The
resulting mixture was stirred at 35uC for 24 hours. After the
solvent was removed in vacuo, the residue was subjected to
HPLC purification (eluting time: 40 minutes). The eluent from
HPLC was concentrated in vacuo at room temperature to
remove the organic solvents. The resulting aqueous solution
was lyophilized to give11N2TFA as a white sticky solid (0.032 g,
33%). The semi-preparative and analytical HPLC retention
times of 11N2TFA are 16.52 and 11.35 minutes, respectively
(see Figure S10 for chromatograms of 11N2TFA before and
after the HPLC purification).
1HN M R( D M S O - d6) d 10.38 (brs,
1H), 7.71 (brs, 6H), 7.51–7.49 (m, 4H), 7.29–7.25 (m, 4H),
7.17–7.14 (m, 2H), 5.96 (s, 1H), 3.35–3.29 (m, 7H), 2.73–2.70 (m,
4H), 2.43 (m, 2H), 2.35 (m, 4H), 2.08 (t, J=7.2 Hz, 2H), 1.48–1.42
(m, 8H), and 1.23–1.18 (m, 12H);
13C NMR (DMSO-d6) d 169.47,
164.32, 158.98 (q), 148.65, 133.40, 128.54, 126.88, 126.36, 125.04,
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27.58, 26.68, 26.39, 21.72, and 19.04; IR cm
21 3428, 3085, 3056,
3023, 2934, 2856, 1679, 1597, 1495, 1201, and 1136; HRMS-ESI
calculated for C38H57N5O4 [M+H
+] 648.4483, found 648.4511.
Synthesis of AHP. 1-Benzyl-N,N-bis(7-(1,3-dioxoisoindolin-
2-yl)heptyl)-4-formyl-5-(3-hydroxy-3,3-diphenylprop-1-ynyl))-1H-
pyrrole-2-carboxamide (38z). A solution of 37x (0.49 g,
1.13 mmol), 14y (0.68 g, 1.35 mmol), BOP (0.99 g, 2.25 mmol),
HOBt (0.30 g, 2.25 mmol) in anhydrous DMF (3 mL) and NMM
(2 mL) was stirred at room temperature for 16 hours. The
reaction mixture was partitioned between water and CH2Cl2.T h e
organic layer was dried over MgSO4, filtered, and concentrated in
vacuo. MPLC purification (Hex:EtOAc/50:50) of the residue gave
38z as a pale yellow oil. (0.72 g, 69%).
1H NMR (CDCl3) d 9.90 (s,
1H), 7.82–7.74 (m, 4H), 7.68–7.64 (m, 4H), 7.56–7.54 (m, 4H),
7.28–7.17 (m, 9H), 7.03–7.00 (m, 2H), 6.59 (s, 1H), 5.36 (s, 2H),
4.37 (brs, 1H), 3.68–3.54 (m, 4H), 3.28–3.18 (m, 2H), 3.06–2.94
(m, 2H), 1.70–1.23 (m, 12H), and 1.18–0.91 (m, 8H);
13C NMR
(CDCl3) d 185.26, 168.69, 162.59, 144.52, 136.86, 134.11,
132.30, 129.55, 128.88, 128.61, 128.13, 127.84, 127.40, 126.19,
125.04, 123.39, 109.02, 102.66, 75.40, 75.13, 49.62, 38.11, 29.13,
28.69, 27.28, 27.09, 26.93, and 26.54.
(E)-Ethyl 3-(1-benzyl-5-bis(7-(1,3-dioxoisoindolin-2-yl)heptyl)-
carbamoyl)-2-(3-hydroxy-3,3-diphenylprop-1-ynyl)-1H-pyrrol-3-
yl)acrylate (39z). To a stirred solution of 38z (0.65 g, 0.71 mmol)
in benzene (20 mL) was added (ethoxycarbonylmethylene)tri-
phenylphosphorane (0.62 g, 1.78 mmol). The resulting mixture
was stirred under reflux for 16 hours. The reaction mixture was
cooled to room temperature and the solvent was removed in
vacuo. MPLC purification (Hex:EtOAc/50:50) of the residue gave
39z as a pale yellow oil (0.54 g, 77%).
1H NMR (CDCl3) d
7.82–7.78 (m, 4H), 7.71–7.67 (m, 5H), 7.57–7.55 (m, 4H),
7.30–7.18 (m, 9H), 7.03–7.02 (m, 2H), 6.39 (s, 1H), 6.24 (d,
J=16.0 Hz, 1H), 5.32 (s, 2H), 4.17 (q, J=7.2 Hz, 2H),
3.68–3.61 (m, 5H), 3.32–3.22 (m, 2H), 3.12–3.01 (m, 2H),
1.70–1.54 (m, 4H), and 1.46–1.00 (m, 19H);
13C NMR (CDCl3) d
168.64, 167.62, 163.06, 145.11, 137.56, 136.88, 134.09, 132.21,
129.06, 128.70, 128.46, 127.79, 127.74, 126.28, 123.66, 123.32,
119.95, 115.76, 108.67, 102.81, 76.66, 75.02, 60.31, 49.38,
45.40, 38.06, 29.11, 28.64, 26.82, and 14.60.
Ethyl 3-(1-benzyl-5-(bis(7-(1,3-dioxoisoindolin-2-yl)heptyl)carbamoyl)
-2-(3-hydroxy-3,3-diphenylpropyl)-1H-pyrrol-3-yl)propanoate (40z).
To a stirred solution of 39z (0.12 g, 0.12 mmol) in EtOAc (20 mL)
was added 10% dry Pd-C (0.012 g). The resulting mixture was
stirred at room temperature for 48 hours under a balloon of
hydrogen. The reaction mixture was filtered through Celite and the
filtrate was concentrated to give 40z as a colorless oil. The crude
product was subjected to the next reaction without further
purification.
1H NMR (CDCl3) d 7.85–7.79 (m, 4H), 7.72–7.67
(m, 4H), 7.36–7.31 (m, 4H), 7.28–7.22 (m, 4H), 7.20–7.11 (m, 5H),
6.78 (d, J=7.2 Hz, 2H), 6.10 (s, 1H), 5.14 (s, 2H), 4.05 (q,
J=6.8 Hz, 2H), 3.64 (t, J=7.2 Hz, 4H), 3.25 (t, J=7.2 Hz, 4H),
2.63 (t, J=7.6 Hz, 2H), 2.50–2.40 (m, 4H), 2.35–2.26 (m, 2H),
1.68–1.58 (m, 4H), and 1.42–1.08 (m, 19H).
N,N-Bis(7-aminoheptyl)-1-benzyl-5-(3-(hydroxy-3,3-diphenyl-
propyl)-4-(3-hydroxyamino)-3-oxopropyl))-1H-pyrrole-2-carbox-
amide (AHP). To a stirred solution of 40z (0.14 g, 0.14 mmol) in
MeOH:THF (2 mL each) was added 50% aqueous hydroxylamine
(4 mL) followed by KCN (0.04 g, 0.56 mmol). The resulting
mixture was stirred at 35uC for 24 hours. After the solvent was
removed in vacuo, the residue was subjected to HPLC purification
(elutingtime:45minutes).TheeluentfromHPLCwasconcentrated
in vacuo at room temperature to remove the organic solvents. The
resulting aqueous solution was lyophilized to give AHPN2TFA as a
white sticky solid (0.034 g, 25%). The semi-preparative and
analytical HPLC retention times of AHPN2TFA are 18.60 and
12.93 minutes, respectively (see Figure S11 for chromatograms of
AHPN2TFA before and after the HPLC purification).
1HN M R
(DMSO-d6) d 10.41 (brs, 1H), 7.71 (brs, 6H), 7.42–7.38 (m, 4H),
7.26–7.10 (m, 9H), 6.67 (d, J=7.2 Hz, 2H), 6.09 (s, 1H), 5.14 (s,
2H), 3.26–3.18 (m, 4H), 2.78–2.62 (m, 4H), 2.48–2.41 (overlapped
with DMSO-d6, 2H), 2.35–2.28 (m, 4H), 2.11 (t, J=7.2 Hz, 2H),
1.50–1.42 (m, 4H), 1.36–1.28 (m, 4H), 1.24–1.12 (m, 8H), and
1.11–1.04 (m, 4H);
13C NMR (DMSO-d6) d 169.46, 164.21, 158.68
(q), 148.59, 140.08, 133.69, 128.91, 128.54, 127.39,126.86, 126.44,
126.28, 124.93, 118.32, 117.57 (q), 111.44, 76.72, 55.61, 47.22,
42.32, 39.40, 34.57, 28.92, 27.58, 26.67, 26.34, 21.78, and 19.05;
IR cm
21 3416, 3085, 3056, 3023, 2934, 2860, 1687, 1614,
1495,1450, 1205, and 1136; HRMS-ESI calculated for
C44H61N5O4 [M+H
+] 724.4796, found 724.4791.
In Vitro Evaluation of AHP
Assays of endopeptidase activities of BoNTAe and BoNTBe were
done at 37uC and contained 0.5 mM substrate, 0.5–1.5 mg/mL
recombinant BoNTAe or BoNTBe, 40 mM HEPES, and 0.05%
tween at pH 7.3. BoNTAe inhibition assays also contained 1 mM
dithiothreitol, 25 mMZ n C l 2, and 0.5 mg/mL BSA, while BoNTBe
inhibition assays were supplemented with 1 mM dithiothreitol only.
Substrate for BoNTAe was an SNAP-25 fragment containing residues
187–203 with N-a n dC-termini acylated and amidated, respectively
[51], while that for BoNTBe was residues 60–94 of VAMP [52].
Inhibitors were dissolved in dimethyl sulfoxide at 10 times the final
assay concentration, then diluted into the assay mixture containing
substrate, followed by addition of the endopeptidase (i.e.,i n h i b i t o ra n d
endopeptidasewere notpreincubated).Assaytimesandendopeptidase
concentrations were adjusted so that less than 10% of the substrate
was hydrolyzed. Assays were stopped by acidification with TFA and
analyzed by reverse-phase HPLC as described [34].
Inhibition of BoNTAe by AHP was determined in three
independent experiments using nine concentrations of AHP in each.
Kiw a sc a l c u l a t e df r o ms l o p e so fD i x o np l o t sw i t ht h ee q u a t i o nKi=Km/
[(slope)(Vmax)(S)], where (S) was the substrate concentration [35].
Kinetic constants for the substrate were taken from reference [36].
MMDSs of the AHPNBoNTAe Complex
The atomic charges of AHP were obtained according to the
RESP procedure [53] with ab initio calculations at the HF/
6-31G*//HF/6-31G* level using the Gaussian 98 program [54].
The starting structure of AHPNBoNTAe was generated by (1)
manually docking AHP into the BoNTAe active site as described
in Section 2.2 and (2) replacing the zinc ion with the tetrahedral
zinc ion of the cationic dummy atom approach [19,43–45]. For
BoNTAe, His223 and His227 were treated as HIN (histidinate)
[44,55,56]; His39, His230, and His269 were treated as HID; all
other His residues were treated as HIP; Glu261 and Glu351 were
treated as GLH [44,55,56]. A total of 39 crystallographically
determined water molecules (named HOH) located inside the
enzyme were included for simulations. The topology and
coordinate files of the water-containing AHPNBoNTAe complex
were generated by the PREP, LINK, EDIT, and PARM modules
of the AMBER 5.0 program [57]. The complex was refined by
energy minimization using a dielectric constant of 1.0 and 100
cycles of steepest-descent minimization followed by 100 cycles of
conjugate-gradient minimization. The refined complex was
solvated with 12,098 TIP3P water molecules (named WAT)
[58], leading to a system of 43,279 atoms. The WAT molecules
were obtained from solvating the complex using a pre-equilibrated
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was set to 0.4170, where any water molecule was removed if it had
an oxygen atom closer than 2.2 A ˚ to any solute atom or a
hydrogen atom closer than 2.0 A ˚ to any solute atom, or if it was
located further than 9.0 A ˚ along the x-, y-, or z-axis from any
solute atom. The solvated complex system were energy-minimized
for 100 cycles of steepest-descent minimization followed by 100
cycles of conjugate-gradient minimization to remove close van der
Waals contacts in the system, then heated from 0 to 300 K at a
rate of 10 K/ps under constant temperature and volume, and
finally simulated independently with a unique seed number for
initial velocities at 300 K under constant temperature and pressure
using the PMEMD module of the AMBER 8.0 program [22] with
the AMBER force field (ff99SB) [59,60].
All simulations used (1) a dielectric constant of 1.0, (2) the
Berendsen coupling algorithm [61], (3) a periodicboundary condition
at a constant temperature of 300 K and a constant pressure of 1 atm
with isotropic molecule-based scaling, (4) the Particle Mesh Ewald
method to calculate long-range electrostatic interactions [62], (5) a
timestep of 1.0 fs,(6) the SHAKE-bond-length constraints applied to
all the bonds involving the H atom, (7) saving the image closest to the
middle of the ‘‘primary box’’ to the restart and trajectory files, (8)
formatted restart file, and (9) default values of all other inputs of the
PMEMD module. These simulations were carried out on a cluster of
300 Apple Xserves each equipped with two G5 processors at a clock
rate of 2.0/2.3 GHz.
Average structures were obtained by using the CARNAL module of
the AMBER 5.0 program. Cluster analyses were performed by using
the PTRAJ module of the AMBER 10 program [22]. RMSDs were
calculated by using the McLachlan algorithm [63] as implemented in
the ProFit program (V2.6, http://www.bioinf.org.uk/software/profit/
). The C&F RMSDs were obtained by (1) generating symmetry mates
within 12 A ˚ using PyMol 0.99rc6 [64], (2) identifying not-free residues
that have a distance of ,8.0 A ˚ between any non-hydrogen atom of the
structure in the primary cell and any non-hydrogen atom of the
symmetry mates, (3) identifying hot residues that have alpha-carbon
atoms with B factors greater than the average B factor for alpha
carbons, (4) identifying short peptides with up to four residues that are
between two hot residues, between two not-free residues, or between a
hot and a not-free residue, (5) deleting the hot and not-free residues and
the short peptides from the crystal structure and from the structure to
be compared, and (6) computing the alpha-carbon RMSD of the
truncated proteins using the ProFit program.
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